pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2007-0-1-117-120pulmo-1899Research ArticleОРГАНИЗАЦИОННЫЕ ВОПРОСЫ ЗДРАВООХРАНЕНИЯHEALTHCARE ORGANIZATIONAL POINTSРешение экспертного совещания "Новые возможности лечения внебольничной пневмонии и бактериального синусита"The conclusion of expert meeting "New treatment perspectives of community-acquired pneumonia and bacterial sinusitis"ЧучалинА. Г.ChuchalinA. G.
г. Москва
БелоусовЮ. Б.BelousovYu. B.
г. Москва
СинопальниковА. И.SinopalnikovA. I.
г. Москва
КозловР. С.KozlovR. S.ФГУ НИИ пульмонологии РосздраваRussian FederationМГМУRussian FederationГВКГ им. Н.Н.БурденкоRussian FederationСмоленский научный институт по антимикробной химиотерапииRussian Federation20072802200701117120Copyright © Чучалин А.Г., Белоусов Ю.Б., Синопальников А.И., Козлов Р.С., 20072007Чучалин А.Г., Белоусов Ю.Б., Синопальников А.И., Козлов Р.С.Chuchalin A.G., Belousov Y.B., Sinopalnikov A.I., Kozlov R.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1899
.
.
ReferencesЗетамакс ретард зарегистрирован в России по показаниям: внебольничная пневмония и острый бактериальный синусит. Инструкция по медицинскому применению препарата Зетамакс ретард одобрена Роздравнадзором 28.07.2006 № 57-Пр-рег/06.Зетамакс ретард зарегистрирован в России по показаниям: внебольничная пневмония и острый бактериальный синусит. Инструкция по медицинскому применению препарата Зетамакс ретард одобрена Роздравнадзором 28.07.2006 № 57-Пр-рег/06.Murray J.J. et al. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol. Head. Neck. Surg. 2005; 133: 194–201.Murray J.J. et al. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol. Head. Neck. Surg. 2005; 133: 194–201.Drehobl M.A., Salvo M.C., Lewis D.E., Breen J.D. Singledose azitromycin microspheres vs. clarithromycin extended release for the treatment of mild-to-moderate community acquired pneumonia in adults. Chest 2005; 128: 2230–2237.Drehobl M.A., Salvo M.C., Lewis D.E., Breen J.D. Singledose azitromycin microspheres vs. clarithromycin extended release for the treatment of mild-to-moderate community acquired pneumonia in adults. Chest 2005; 128: 2230–2237.D'Ignazio J., Camere M. A., Lewis D.E. et al. Novel, singledose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob. Agents Chemother. 2005; 49 (10): 4035–41D'Ignazio J., Camere M. A., Lewis D.E. et al. Novel, singledose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob. Agents Chemother. 2005; 49 (10): 4035–41FDA. Labeling Requirements for Systemic Antibacterial Drug Products Intended for Human use. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/00n-1463nfr00001.pdfFDA. Labeling Requirements for Systemic Antibacterial Drug Products Intended for Human use. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/00n-1463nfr00001.pdfKardas P., Devine S., Golembesky A., Roberts C. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Inter. J. Antimicrob. Agents 2005. 26: 106–113.Kardas P., Devine S., Golembesky A., Roberts C. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Inter. J. Antimicrob. Agents 2005. 26: 106–113.
The authors declare that there are no conflicts of interest present.